Immune response to dengue virus and prospects for a vaccine
- PMID: 21219187
- DOI: 10.1146/annurev-immunol-031210-101315
Immune response to dengue virus and prospects for a vaccine
Abstract
Dengue virus (DENV) is a mosquito-borne member of the Flavivirus genus and includes four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), each of which is capable of causing dengue fever and dengue hemorrhagic fever/dengue shock syndrome. Serious disease can be seen during primary infection but is more frequent following second infection with a serotype different from that of a previous infection. Infection with wild-type DENV induces high-titered neutralizing antibody that can provide long-term immunity to the homotypic virus and can provide short-term immunity (only several months duration) to a heterotypic DENV. The high level of virus replication seen during both secondary infection with a heterotypic virus and during primary DENV infection in late infancy is a direct consequence of antibody-dependent enhancement of replication. This enhanced virus replication is mediated primarily by preexisting, nonneutralizing, or subneutralizing antibodies to the virion surface antigens that enhance access of the virion-antibody complex to FcγR-bearing cells. Vaccines will need to provide long-term protection against each of the four DENV serotypes by inducing neutralizing antibodies, and live, attenuated and various nonliving virus vaccines are in development.
Similar articles
-
Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.J Virol. 2015 Jul;89(14):7348-62. doi: 10.1128/JVI.00273-15. J Virol. 2015. PMID: 25972550 Free PMC article. Clinical Trial.
-
CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.J Virol. 2015 Jun;89(12):6494-505. doi: 10.1128/JVI.00036-15. Epub 2015 Apr 8. J Virol. 2015. PMID: 25855749 Free PMC article.
-
Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.J Virol. 2021 Jan 28;95(4):e00658-20. doi: 10.1128/JVI.00658-20. Print 2021 Jan 28. J Virol. 2021. PMID: 33208445 Free PMC article.
-
Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.Front Immunol. 2019 Jun 11;10:1316. doi: 10.3389/fimmu.2019.01316. eCollection 2019. Front Immunol. 2019. PMID: 31244855 Free PMC article. Review.
-
Dengue virus vaccine development.Adv Virus Res. 2014;88:315-72. doi: 10.1016/B978-0-12-800098-4.00007-6. Adv Virus Res. 2014. PMID: 24373316 Review.
Cited by
-
Multiantibody strategies for HIV.Clin Dev Immunol. 2013;2013:632893. doi: 10.1155/2013/632893. Epub 2013 Jun 6. Clin Dev Immunol. 2013. PMID: 23840243 Free PMC article. Review.
-
Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination.PLoS One. 2012;7(12):e51244. doi: 10.1371/journal.pone.0051244. Epub 2012 Dec 10. PLoS One. 2012. PMID: 23251466 Free PMC article.
-
Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.Expert Rev Vaccines. 2012 Feb;11(2):177-87. doi: 10.1586/erv.11.180. Expert Rev Vaccines. 2012. PMID: 22309667 Free PMC article. Review.
-
Dengue: A Minireview.Viruses. 2020 Jul 30;12(8):829. doi: 10.3390/v12080829. Viruses. 2020. PMID: 32751561 Free PMC article. Review.
-
Assessing the global threat from Zika virus.Science. 2016 Aug 12;353(6300):aaf8160. doi: 10.1126/science.aaf8160. Epub 2016 Jul 14. Science. 2016. PMID: 27417495 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical